Menu
Back to User profile » Professor Dandan Hu
Papers published by Professor Dandan Hu:
Efficacy and Safety of Conversion Surgery for Advanced Hepatocellular Carcinoma After Hepatic Arterial Infusion Chemotherapy
Li W, Zheng Z, Wang J, Wu T, Wang J, Pan Y, Chen J, Hu D, Xu L, Zhang Y, Chen M, Zhou Z
Journal of Hepatocellular Carcinoma 2024, 11:463-475
Published Date: 4 March 2024
Systemic Inflammation Score Using Pretherapeutic Inflammatory Markers to Predict Prognosis for Hepatocellular Carcinoma Patients After Hepatic Arterial Infusion Chemotherapy
Wu T, Zheng Z, Wang J, He M, Wang J, Pan Y, Chen J, Hu D, Zhang Y, Xu L, Chen M, Zhou Z
Journal of Hepatocellular Carcinoma 2023, 10:2133-2145
Published Date: 1 December 2023
Tenofovir versus Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma After FOLFOX-Hepatic Arterial Infusion Chemotherapy
Zheng Z, Wang J, Wu T, He M, Wang J, Pan Y, Chen J, Hu D, Xu L, Zhang Y, Chen M, Zhou Z
Journal of Hepatocellular Carcinoma 2023, 10:2117-2132
Published Date: 30 November 2023
Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
Long T, Yang Z, Zeng H, Wu W, Hu Z, Yang Z, Hu D, Zhou Z, Chen M, Zhang Y
Journal of Hepatocellular Carcinoma 2023, 10:1849-1859
Published Date: 20 October 2023
Laparoscopic Hepatectomy versus Open Hepatectomy After Conversion Therapy Using Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy for Patients with Initially Unresectable Hepatocellular Carcinoma
Yang Z, Hu Z, Fu Y, Hu D, Zhou Z, Chen M, Pan Y, Zhang Y
Journal of Hepatocellular Carcinoma 2023, 10:1157-1167
Published Date: 21 July 2023
A Systemic Inflammation Response Score for Prognostic Prediction in Hepatocellular Carcinoma Patients After Hepatectomy
Zhang D, Huo L, Pan Y, Yang Z, Zeng H, Wang X, Chen J, Wang J, Zhang Y, Zhou Z, Chen M, Hu D
Journal of Inflammation Research 2022, 15:6869-6881
Published Date: 29 December 2022
Inflammation-Based Scores Predict Responses to PD-1 Inhibitor Treatment in Intrahepatic Cholangiocarcinoma
Yang Z, Zhang D, Zeng H, Fu Y, Hu Z, Pan Y, Chen J, Wang J, Zhang Y, Zhou Z, Xu L, Hu D, Chen M
Journal of Inflammation Research 2022, 15:5721-5731
Published Date: 6 October 2022
Hepatic Arterial Infusion Chemotherapy as a Timing Strategy for Conversion Surgery to Treat Hepatocellular Carcinoma: A Single-Center Real-World Study
Wang J, Zheng Z, Wu T, Li W, Wang J, Pan Y, Peng W, Hu D, Hou J, Xu L, Zhang Y, Chen M, Zhang R, Zhou Z
Journal of Hepatocellular Carcinoma 2022, 9:999-1010
Published Date: 14 September 2022
Prognostic Values of Alpha-Fetoprotein and Des-Gamma-Carboxyprothrombin in Hepatocellular Carcinoma in China: An Analysis of 4792 Patients
Pan YX, Sun XQ, Hu ZL, Xie W, Nie KX, Fang AP, Zhang YY, Fu YZ, Chen JB, Wang JC, Wang X, Zhang YJ, Hu DD, Chen MS
Journal of Hepatocellular Carcinoma 2021, 8:657-670
Published Date: 25 June 2021
Can Immediately Treating Subcentimeter Hepatocellular Carcinoma Improve the Survival of Patients?
Sun X, Hu D, Zhang Y, Lyu N, Xu L, Chen Q, Lai J, Chen M, Zhao M
Journal of Hepatocellular Carcinoma 2020, 7:377-384
Published Date: 16 December 2020
Baseline HBV Loads Do Not Affect the Prognosis of Patients with Hepatocellular Carcinoma Receiving Anti-Programmed Cell Death-1 Immunotherapy
Sun X, Hu D, Yang Z, Liu Z, Wang J, Chen J, Xu L, Zhou Z, Chen M, Zhang Y
Journal of Hepatocellular Carcinoma 2020, 7:337-345
Published Date: 1 December 2020